MCID: PLM038
MIFTS: 37

Pulmonary Large Cell Neuroendocrine Carcinoma malady

Categories: Cancer diseases, Respiratory diseases, Neuronal diseases

Aliases & Classifications for Pulmonary Large Cell Neuroendocrine Carcinoma

Aliases & Descriptions for Pulmonary Large Cell Neuroendocrine Carcinoma:

Name: Pulmonary Large Cell Neuroendocrine Carcinoma 12 14
Large Cell Lung Neuroendocrine Carcinoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:6658
NCIt 47 C5672 C6875
SNOMED-CT 64 128628002

Summaries for Pulmonary Large Cell Neuroendocrine Carcinoma

MalaCards based summary : Pulmonary Large Cell Neuroendocrine Carcinoma, also known as large cell lung neuroendocrine carcinoma, is related to large cell neuroendocrine carcinoma and peroneal nerve paralysis, and has symptoms including coughing, dyspnea and fever. An important gene associated with Pulmonary Large Cell Neuroendocrine Carcinoma is VGF (VGF Nerve Growth Factor Inducible), and among its related pathways/superpathways is Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and prostate, and related phenotypes are behavior/neurological and nervous system

Related Diseases for Pulmonary Large Cell Neuroendocrine Carcinoma

Diseases related to Pulmonary Large Cell Neuroendocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Related Disease Score Top Affiliating Genes
1 large cell neuroendocrine carcinoma 10.5
2 peroneal nerve paralysis 10.2 CHGA SYP
3 thymus small cell carcinoma 10.2 CHGA SYP
4 brain stem ependymoma 10.2 CHGA SYP
5 non specific chronic endometritis 10.2 CHGA SYP
6 extrahepatic biliary papillomatosis 10.2 CHGA SYP
7 prolactin producing pituitary tumor 10.2 CHGA SYP
8 epithelioid malignant peripheral nerve sheath tumor 10.2 CHGA SYP
9 cartilage cancer 10.2 CHGA SYP
10 villous adenocarcinoma 10.2 CHGA SYP
11 jejunal neuroendocrine tumor 10.2 CHGA SYP
12 renal pelvis adenocarcinoma 10.2 CHGA SYP
13 spasmodic dysphonia 10.2 CHGA SYP
14 microinvasive cervical squamous cell carcinoma 10.2 CHGA SYP
15 perineural angioma 10.2 CHGA SYP
16 gastric duplication cysts 10.2 CHGA SYP
17 diffuse cutaneous mastocytosis 10.2 CHGA SYP
18 main bronchus cancer 10.2 CHGA SYP
19 gliofibroma 10.2 CHGA SYP
20 cavernous hemangioma of face 10.2 CHGA SYP
21 adult botryoid rhabdomyosarcoma 10.1 CHGA SYP
22 superior vena cava syndrome 10.1 CHGA SYP
23 exudative glomerulonephritis 10.1 CHGA SYP
24 fragile x-associated tremor/ataxia syndrome 10.1 CHGA SYP
25 hepatorenal syndrome 10.1 CHGA SYP
26 acalculous cholecystitis 10.1 CHGA SYP
27 piussan lenaerts mathieu syndrome 10.1 CHGA SYP
28 brain stem astrocytic neoplasm 10.1 CHGA SYP
29 anal squamous cell carcinoma 10.1 CHGA SYP
30 calcific tendinitis 10.1 CHGA SYP
31 mitochondrial complex ii deficiency 10.1 CHGA SYP
32 bone marrow cancer 10.1 CHGA SYP
33 dysgerminoma of ovary 10.1 CHGA SYP
34 pediculus humanus corporis infestation 10.1 CHGA SYP
35 acinar cell cystadenocarcinoma 10.1 CHGA SYP
36 hunter macpherson syndrome 10.1 CHGA SYP
37 cowden syndrome 3 10.1 CHGA SYP
38 ampulla of vater mucinous adenocarcinoma 10.1 CHGA SYP
39 thymus squamous cell carcinoma 10.1 CHGA SYP
40 growth retardation hydrocephaly lung hypoplasia 10.1 CHGA SYP
41 testicular trophoblastic tumor 10.1 CHGA SYP
42 bone dysplasia azouz type 10.1 CHGA SYP
43 cardioauditory syndrome of sanchez cascos 10.1 CHGA SYP
44 eccrine papillary adenocarcinoma 10.1 CHGA SYP
45 t-cell adult acute lymphocytic leukemia 10.1 CHGA SYP
46 clear cell variant infiltrating bladder urothelial carcinoma 10.1 CHGA SYP
47 inner ear cancer 10.1 CHGA SYP
48 sternum lymphoma 10.1 CHGA SYP
49 struma ovarii 10.1 CHGA SYP
50 rh isoimmunization 10.1 NTRK2 SYP

Graphical network of the top 20 diseases related to Pulmonary Large Cell Neuroendocrine Carcinoma:



Diseases related to Pulmonary Large Cell Neuroendocrine Carcinoma

Symptoms & Phenotypes for Pulmonary Large Cell Neuroendocrine Carcinoma

UMLS symptoms related to Pulmonary Large Cell Neuroendocrine Carcinoma:


coughing, dyspnea, fever, hemoptysis

MGI Mouse Phenotypes related to Pulmonary Large Cell Neuroendocrine Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.35 VGF ASCL1 CHL1 NTRK2 SYP
2 nervous system MP:0003631 9.02 ASCL1 CHL1 NTRK2 SYP VGF

Drugs & Therapeutics for Pulmonary Large Cell Neuroendocrine Carcinoma

Drugs for Pulmonary Large Cell Neuroendocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 4,Phase 2 41575-94-4 10339178 498142 38904
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1 22916-47-8 4189
4
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177
5
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 5284616 6436030 46835353
6 Albumin-Bound Paclitaxel Phase 4,Phase 2,Phase 1
7 Anti-Bacterial Agents Phase 4,Phase 1
8 Anti-Infective Agents Phase 4,Phase 1
9 Immunosuppressive Agents Phase 4,Phase 1
10 Antifungal Agents Phase 4,Phase 1
11 Antibiotics, Antitubercular Phase 4,Phase 1
12 Antimitotic Agents Phase 4,Phase 1,Phase 2
13 Antineoplastic Agents, Phytogenic Phase 4,Phase 1,Phase 2
14
Somatostatin Approved Phase 1, Phase 2 38916-34-6, 51110-01-1 53481605
15
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
16
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
17
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
18
Succinylcholine Approved Phase 1, Phase 2 306-40-1 5314
19
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
20 Topoisomerase Inhibitors Phase 1, Phase 2
21 Hormones Phase 1, Phase 2
22 Hormone Antagonists Phase 1, Phase 2
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2
24 Podophyllotoxin Phase 1, Phase 2 518-28-5
25 Neuromuscular Agents Phase 1, Phase 2
26 Neuromuscular Blocking Agents Phase 1, Phase 2
27 Neuromuscular Depolarizing Agents Phase 1, Phase 2
28 Dermatologic Agents Phase 1, Phase 2
29 Peripheral Nervous System Agents Phase 1, Phase 2
30 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
31 Etoposide phosphate Phase 1, Phase 2
32 Keratolytic Agents Phase 1, Phase 2
33
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
34
Octreotide Approved, Investigational Phase 1 83150-76-9 383414 6400441
35
rituximab Approved Phase 1 174722-31-7 10201696
36
Pembrolizumab Approved Phase 1 1374853-91-4
37
Docetaxel Approved May 1996, Investigational Phase 1 114977-28-5 148124 9877265
38
Doxil Approved June 1999 Phase 1 31703
39 pancreatic polypeptide Phase 1
40 calcium channel blockers Phase 1
41 Gastrointestinal Agents Phase 1
42 Vaccines Phase 1
43 Edotreotide Phase 1
44 Radiopharmaceuticals Phase 1
45 Antineoplastic Agents, Hormonal Phase 1
46 Calcium, Dietary Phase 1
47 Carboxyamido-triazole Phase 1
48 Immunoglobulin G Phase 1
49 Immunoglobulins Phase 1
50 Antibodies, Monoclonal Phase 1

Interventional clinical trials:

(show all 21)
id Name Status NCT ID Phase
1 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
2 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed NCT01177397 Phase 1, Phase 2
3 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2
4 uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung Recruiting NCT02755675 Phase 2
5 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Recruiting NCT02568267 Phase 2
6 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer Active, not recruiting NCT01642251 Phase 1, Phase 2
7 Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma Not yet recruiting NCT02943798 Phase 2
8 Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas Withdrawn NCT02030184 Phase 1, Phase 2
9 Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features Unknown status NCT00314925 Phase 1
10 Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies Completed NCT00703625 Phase 1
11 Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies Completed NCT00703170 Phase 1
12 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
13 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas Completed NCT00019019 Phase 1
14 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
15 SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma Recruiting NCT02500914 Phase 1
16 Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Recruiting NCT02595866 Phase 1
17 A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Recruiting NCT01307267 Phase 1
18 Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Active, not recruiting NCT01165658 Phase 1
19 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
20 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
21 Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy Recruiting NCT02357992

Search NIH Clinical Center for Pulmonary Large Cell Neuroendocrine Carcinoma

Genetic Tests for Pulmonary Large Cell Neuroendocrine Carcinoma

Anatomical Context for Pulmonary Large Cell Neuroendocrine Carcinoma

MalaCards organs/tissues related to Pulmonary Large Cell Neuroendocrine Carcinoma:

39
Lung, Brain, Prostate, Bronchial Epithelium

Publications for Pulmonary Large Cell Neuroendocrine Carcinoma

Articles related to Pulmonary Large Cell Neuroendocrine Carcinoma:

(show all 35)
id Title Authors Year
1
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. ( 26960398 )
2016
2
Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401). ( 27903179 )
2016
3
PS01.24: Clinical Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma Characterized by Next-Generation Sequencing: Topic: Medical Oncology. ( 27969491 )
2016
4
Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma. ( 27368130 )
2016
5
Pulmonary large-cell neuroendocrine carcinoma presenting as multiple cutaneous metastases. ( 26176530 )
2015
6
Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma. ( 26060407 )
2015
7
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. ( 26039012 )
2015
8
Cutaneous metastasis from pulmonary large cell neuroendocrine carcinoma in the scalp. ( 24966991 )
2014
9
Pulmonary large cell neuroendocrine carcinoma exhibiting extensive pagetoid spread in the bronchial epithelium: A case report. ( 25364438 )
2014
10
Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy. ( 22498090 )
2013
11
TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell neuroendocrine carcinoma. ( 23312550 )
2013
12
Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma. ( 24649189 )
2013
13
Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma. ( 24023298 )
2013
14
Prostatic metastasis of pulmonary large cell neuroendocrine carcinoma. ( 22359531 )
2012
15
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? ( 22579297 )
2012
16
Pulmonary large cell neuroendocrine carcinoma diagnosed in a brain metastasis. ( 22400077 )
2012
17
Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. ( 22977617 )
2011
18
Pulmonary large cell neuroendocrine carcinoma: a true high-grade neuroendocrine tumor needing prospective therapeutic data. ( 21918393 )
2011
19
Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. ( 20398190 )
2010
20
Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. ( 19619794 )
2009
21
A new possible lung cancer marker: VGF detection from the conditioned medium of pulmonary large cell neuroendocrine carcinoma-derived cells using secretome analysis. ( 20082272 )
2009
22
A long-term survivor with pulmonary large-cell neuroendocrine carcinoma. ( 17706407 )
2007
23
Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. ( 17643676 )
2007
24
Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. ( 16862075 )
2006
25
Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. ( 17062251 )
2006
26
Identification of tumor suppressor loci on the long arm of chromosome 5 in pulmonary large cell neuroendocrine carcinoma. ( 16236978 )
2005
27
Cytological characteristics of pulmonary large cell neuroendocrine carcinoma. ( 15893001 )
2005
28
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. ( 15538626 )
2005
29
Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. ( 15022286 )
2004
30
Imprint cytologic features of pulmonary large cell neuroendocrine carcinoma: Comparison with classic large cell carcinoma. ( 14719055 )
2004
31
Pulmonary large cell neuroendocrine carcinoma demonstrates high proliferative activity. ( 15172230 )
2004
32
Pulmonary large-cell neuroendocrine carcinoma (LCNEC). ( 12694759 )
2003
33
High survival rate of 6 cases of pulmonary large cell neuroendocrine carcinoma formerly classified as small cell carcinoma. ( 11505281 )
2001
34
Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. ( 11391577 )
2001
35
Myasthenic (Eaton-Lambert) syndrome associated with pulmonary large-cell neuroendocrine carcinoma. ( 7973914 )
1994

Variations for Pulmonary Large Cell Neuroendocrine Carcinoma

Expression for Pulmonary Large Cell Neuroendocrine Carcinoma

Search GEO for disease gene expression data for Pulmonary Large Cell Neuroendocrine Carcinoma.

Pathways for Pulmonary Large Cell Neuroendocrine Carcinoma

Pathways related to Pulmonary Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.53 ASCL1 SYP

GO Terms for Pulmonary Large Cell Neuroendocrine Carcinoma

Cellular components related to Pulmonary Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.33 CHGA SYP VGF
2 transport vesicle GO:0030133 8.96 CHGA VGF
3 terminal bouton GO:0043195 8.62 NTRK2 SYP

Biological processes related to Pulmonary Large Cell Neuroendocrine Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.5 ASCL1 CHL1 NTRK2
2 cerebral cortex development GO:0021987 9.26 ASCL1 NTRK2
3 oligodendrocyte differentiation GO:0048709 9.16 ASCL1 NTRK2
4 central nervous system neuron development GO:0021954 8.96 ASCL1 NTRK2
5 neuron migration GO:0001764 8.8 ASCL1 CHL1 NTRK2

Sources for Pulmonary Large Cell Neuroendocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....